Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328069 | 0.83 | — | — | |
| SCHEMBL12314754 | 0.82 | DGAT1 (0.32) | — | |
| SCHEMBL12647109 | 0.82 | — | — | |
| SCHEMBL14309727 | 0.82 | LPL (0.32) | — | |
| SCHEMBL13100018 | 0.81 | HCAR3 (0.34) | — | |
| SCHEMBL13474635 | 0.80 | LPL (0.38) | — | |
| SCHEMBL13620527 | 0.79 | DGAT1 (0.40) | — | |
| SCHEMBL10085659 | 0.79 | LPL (0.33) | — | |
| SCHEMBL10441880 | 0.78 | DGAT1 (0.30) | — | |
| SCHEMBL13100020 | 0.77 | HCAR3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2009067600-A2 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | NOS3 3303/4885NOS2 3628/4885 |
| US-20100130522-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, CXCL8, CCR9 | NOS3 881/4885NOS2 763/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | NOS3 100/4885NOS2 94/4885 |
| US-20120225859-A1 | PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS | PIK3CA, PI4KA, PI4KB | NOS3 3254/4885NOS2 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.